ALGEN genOway Société anonyme

2.062USD1.880 EUR · EPA0.00%Mkt Cap: 26.39M USDP/E: —

genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as k…

Key Statistics

Company
Market Cap26.39M USD
Enterprise Value—
Revenue (TTM)26.96M USD
Gross Profit11.24M USD
Net Income (TTM)1.02M USD
Revenue/Share—
Last Price2.062 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0004053510
Valuation
P/E (Trailing)—
P/E (Forward)13.00
PEG—
EV/EBITDA—
EV/Revenue—
P/S0.98
P/B1.06
EPS (TTM)-0.16 USD
EPS (Forward)0.16 USD
52W Range
1.9857% of range3.159
52W High3.159 USD
52W Low1.985 USD
Profitability
Gross Margin48.90%
Oper. Margin-5.67%
EBITDA Margin8.46%
Profit Margin4.43%
ROE3.71%
ROA2.05%
ROIC2.11%
ROCE1.76%
Growth
Revenue Growth-12.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.56M USD
CapEx (TTM)11.98M USD
FCF Margin-16.82%
FCF Yield-17.18%
Net Debt13.08M USD
Net Debt/EBITDA5.74
Net Debt/FCF—
Balance Sheet
Debt/Equity0.55
Current Ratio2.40
Quick Ratio2.10
Book Value/Sh2.01 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.12.34M
Float—
Insiders31.39%
Institutions13.81%
Technical
SMA 502.422 (-14.9%)
SMA 2002.611 (-21.0%)
Beta0.44
S&P 52W Chg12.00%
Avg Vol (30d)9.45K
Avg Vol (10d)9.03K
Technical Indicators
RSI (14)35.1
MACD-0.0837
MACD Signal-0.0839
MACD Hist.+0.0002
BB Upper2.418 USD
BB Middle2.203 USD
BB Lower1.988 USD
BB Width19.55%
ATR (14)0.1179 USD
Vol Ratio (20d)0.86x

About genOway (EPA: ALGEN)

›

genOway (EPA: ALGEN) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 1.880 EUR on 19 November 2026, down 26.0% over 52 weeks. Its 52-week range is 1.810 EUR to 2.880 EUR: the price is 34.7% below the high and 3.9% above the low.

Its market capitalisation is 24.06M EUR.

genOway reports return on equity of 3.7%, an operating margin of -5.7% and revenue down 12.4% year over year.

Its debt exceeds its cash by 11.92M EUR, a debt-to-equity ratio of 0.55. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.